Tuberculosis preventive treatment in people living with HIV—Is the glass half empty or half full?
Open Access
- 14 September 2021
- journal article
- editorial
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (9) , e1003702
Abstract
Olivia Oxlade and co-authors introduce a Collection on tuberculosis preventive therapy in people with HIV infection.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-003634)
This publication has 15 references indexed in Scilit:
- New opportunities in tuberculosis prevention: implications for people living with HIVJournal of the International AIDS Society, 2020
- Advancing global tuberculosis control after the UNGA-HLMThe Lancet, 2018
- The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2016
- The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical ModellingPLOS Medicine, 2016
- Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIVAIDS, 2016
- Pharmacological Interactions Between Rifampicin and Antiretroviral DrugsTherapeutic Drug Monitoring, 2015
- Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative people at risk of active TBEvidence-Based Child Health: A Cochrane Review Journal, 2014
- Treatment of latent tuberculosis infection in HIV infected personsCochrane Database of Systematic Reviews, 2010
- Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysisClinical Infectious Diseases, 2005
- Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.2001